Syntekabio to Showcase Biologics Discovery Platform at PEGS Boston tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
EQS-News: Heidelberg Pharma AG / Key word: Quarterly / Interim Statement
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
25.04.2024 /.
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82%690 subjects analyzed including.